Introduction
Proscia is a Philadelphia-based software company founded in 2014 that accelerates pathology’s transition to digital, AI-augmented workflows. David West, co-founder, serves as chief executive officer per Proscia’s leadership page. Coleman Stavish is chief technology officer and Nathan Buchbinder is chief strategy officer — both co-founders alongside West from Johns Hopkins and University of Pittsburgh engineering backgrounds.
Proscia’s Concentriq platform manages millions of pathology cases annually across biopharmaceutical and diagnostic laboratory customers, positioning pathology images as structured data inputs for drug discovery, companion diagnostics, and clinical case review. Fifth Generation Concentriq, launched June 2026, represents Proscia’s bet that AI-native architecture outperforms legacy viewers retrofitted with models.
What the company does
Proscia provides Concentriq, an enterprise pathology platform for storing, managing, and analyzing whole-slide images across clinical diagnostics and life-sciences research. The June 2026 Fifth Generation release introduces an AI-native architecture intended to embed intelligence into everyday case review and scientific workflows rather than requiring separate AI applications per use case. Proscia also offers Concentriq Embeddings and real-world pathology datasets to accelerate customer AI development.
Concentriq handles case routing, quality assurance, and collaboration for distributed pathology teams — functions that become critical as laboratories adopt hybrid sign-out models where pathologists review cases remotely across time zones. Fifth Generation’s AI-native layer targets invisible administrative steps West has described publicly: gathering case context, verifying completeness, and preparing structured inputs before pathologists apply diagnostic judgment.
Pharma R&D teams use Concentriq to manage pathology endpoints in multi-site trials where slide consistency and audit trails matter as much as algorithm accuracy — a use case Proscia emphasizes when citing top-twenty pharmaceutical adoption.
Who it serves
Proscia serves diagnostic laboratories running high-volume case review — including customers cited in its Fifth Generation launch such as PathGroup and IQVIA Laboratories — and pharmaceutical organizations using digital pathology in clinical trials and biomarker programs. Proscia states that sixteen of the top twenty pharmaceutical companies run on Concentriq, reflecting its strength in research and development workflows alongside clinical lab adoption.
Biomarker program managers need pathology platforms that version-control algorithm updates across global trial sites — a governance requirement Proscia targets with enterprise Concentriq deployments rather than desktop slide viewers.
Company background
West, Stavish, and Buchbinder founded Proscia in 2014 in Philadelphia while completing biomedical and computer science training. The company raised significant venture funding, including a March 2025 $50 million round led by Insight Partners to weave AI deeper into Concentriq’s core. Proscia has pursued FDA 510(k) clearance and CE-IVDR certification for diagnostic software and expanded enterprise deployments as pathology labs face pathologist workforce constraints.
Proscia’s Johns Hopkins and University of Pittsburgh founder pedigree shaped early product focus on whole-slide image management before AI became the category headline — a platform-first origin that differs from algorithm-only startups retrofitting viewers later.
Product and AI capabilities
Proscia’s Fifth Generation Concentriq applies a first-principles AI layer designed to reduce invisible labor around case review — administrative context gathering, quality checks, and workflow routing — so pathologists and scientists focus on judgment calls. CTO Coleman Stavish framed the release as working backwards from how pathologists operate rather than adding generic models to legacy viewers. Customer quotes from PathGroup and IQVIA in Proscia’s press release emphasize removing process burden while preserving expert sign-out authority.
Concentriq Embeddings and real-world image datasets let pharma customers train foundation models on pathology archives without exporting slides to unsecured environments — an enterprise requirement as algorithm count explodes.
Key developments
2014: Proscia founded in Philadelphia. March 19, 2025: $50M funding led by Insight Partners announced for Concentriq AI expansion. June 17, 2026: Fifth Generation Concentriq launched with AI-native architecture (official press release).
Proscia’s 2026 Fifth Generation launch followed KLAS recognition and Labcorp adoption announcements referenced in its 2025–2026 press materials — a sequence suggesting enterprise pathology buyers validated platform scale before AI-native architecture shipped broadly.
Why it matters
Proscia matters because digital pathology platforms — not standalone algorithms — may determine which AI tools scale in regulated laboratories. West has publicly challenged the narrative that AI replaces pathologists, arguing instead for eliminating administrative burden while expanding pathology’s role in precision medicine. Fifth Generation is Proscia’s 2026 wager that platform-native intelligence outcompetes bolt-on AI in both pharma R&D and clinical diagnostics.
Lab CIOs comparing Proscia to scanner-vendor software should evaluate open API ecosystems and algorithm marketplaces — lock-in risk rises when primary diagnosis runs on a single vendor stack without portable data export policies.
Sector context
Proscia belongs in Brel’s AI in healthcare coverage under digital pathology, alongside algorithm vendors such as PathAI and Ibex Medical Analytics and data platforms like Tempus AI. Buyers should evaluate whether they need a platform vendor (Proscia) or a specific diagnostic algorithm — many health systems ultimately require both, integrated deliberately.
Tempus AI’s acquisition of Paige illustrates upstream consolidation affecting pathology data assets — Proscia customers should monitor how pharma partners route trial slides across platform and algorithm vendors when designing long-term digital pathology strategy.
Sources and references
Proscia Fifth Generation press release (June 17, 2026) and Leadership page.
- Proscia — Fifth Generation Concentriq (proscia.com, June 17, 2026)
- Proscia — Leadership (proscia.com)
Reviewed July 10, 2026. David West is CEO and co-founder.